Browsing Tag

Oncology

Advanced Technology Laboratory, Cytogenetics, Flow Cytometry, General Information, Molecular Diagnostics

Spectrum Health Advanced Technology Laboratory featured on WXMI, Fox 17

Spectrum Health Regional Laboratory (SHRL) was featured on Medical Moment on Fox 17 News, Monday, September 19, 2016. Watch the clip below to go behind the scenes of our Advanced Technology Laboratories with Kim Collison, Director of Laboratory Services. Learn how ATL provides rapid turn-around of unique testing performed right here in West Michigan, which supports many key services such as oncology.

For more information on the testing that SHRL and ATL offer, please visit our Laboratory Catalog.

Advanced Technology Laboratory, Cytogenetics, Flow Cytometry, General Information, Molecular Diagnostics

Advanced Technology Laboratory plays an important role in Oncology

Spectrum Health Regional Laboratory (SHRL) was featured on EightWest on WOOD TV8 on Tuesday, August 30, 2016. Dr. Stephanie F. Williams, Division Chief of Spectrum Health Adult Bone and Marrow Transplant, and Kim Collison, Director of Laboratory Services, talk about the importance and benefits of having SHRL’s Advanced Technology Laboratory right here in West Michigan.

The Advanced Technology Laboratory is “extremely important, particularly for patients with certain cancers…”

“It helps us to diagnose the patients faster and more accurately; to follow the progress of their disease during the treatments that we give, and even at times to guide us in what is the best treatment for a patient…”

“Within 2 hours we had the answer. We did not have to send that specimen out to another laboratory in another state.”

-Stephanie F. Williams, MD, Division Chief, Spectrum Health Adult Bone and Marrow Transplant

Advanced Technology Laboratory, Cytogenetics, Molecular Diagnostics, Test Spotlight

Lung Cancer Mutation Analysis Panel provides targeted treatments for patients

The treatment of non-small cell lung adenocarcinoma has become more successful due to targeted treatments based on the molecular profile of a patient’s particular tumor. The Lung Cancer Mutation Analysis panel is now available for clinical testing at the Spectrum Health Advanced Technology Laboratories (ATL).  Continue Reading

Chemistry, Referral/Sendouts, Test Utilization

Appropriate Thyroglobulin Tumor Marker and Anti-Thyroperoxidase Ordering Practices

Thyroid Peroxidase Antibody (anti-TPO), Blood Level (Test #8524 )
This is the recommended test for the evaluation of Autoimmune Thyroiditis

Thyroglobulin, Tumor Marker, Serum (Test #3069)
It is only indicated for monitoring of thyroid cancer treatment.
This result is reported with an Anti-Tg result to assess for possible interference.
This test should NOT be ordered for associated anti-Tg result provided by reference laboratory.

Thyroglobulin Antibody (anti-Tg) Test
Historically ordered with anti-TPO for evaluation of possible autoimmune thyroiditis.
The literature shows that anti-TPO, alone, has better sensitivity and specificity with only 5% of cases of Autoimmune thyroiditis with anti-TPO negative, anti-Tg positive.
Since 2/2011, requests for anti-Tg have been cancelled per Laboratory Communication: Memo Thyroglobulin Antibody 2/2011

Spectrum Health Regional Laboratory Experience February 2015 – March 2016 (13 months):
357 patients with both Anti-TPO and Anti-Tg results.
*Anti-Tg results were due to concomitantly ordered Thyroglobulin TM requests.
250 patients had positive Anti-TPO and/or Anti-Tg level
193 patients had both positive Anti-TPO and Anti-Tg level
56 patients had positive Anti-TPO and negative Anti-Tg level
1 patient had a negative Anti-TPO and positive Anti-Tg levels

Based on these results, and what is reported in the literature, we are confident of our current practices and strongly request discontinuation of Thyroglobulin TM requests for the associated Anti-Tg result

Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014 Apr-May;13(4-5):391-7

Hematology

Peripheral Blood Smear Reminder

As of January 12, 2016, pathologist review of peripheral blood smear ordered without accompanying CBC with differential will reflex to adding on a CBC and/or differential in the laboratory. Blood specimens that do not have a slide prepared need to be less than 6 hours old for a pathologist review to be added on.

This is due to the fact that older blood does not smear well and morphology is compromised, especially red cell morphology. This allows for a complete documentation of the patient’s CBC and differential findings in the electronic medical record and standardizes our process among the regional hospitals.

Any questions concerning Peripheral Blood Smear reflexes should be directed to Dr. Jennifer Stumph, Director of Hematology.